Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Marine Snail Venom Could Yield Novel Opioid Alternative

By Kenny Walter, Digital Reporter | March 2, 2017

A new alternative to opioids has emerged from an unlikely place.

Scientists at the University of Utah have found a compound in Conus regius, a small marine cone snail common to the Caribbean Sea, that blocks pain by targeting a pathway not associated with opioids.

In the study, researchers found that a compound isolated from the snail’s venom—Rg1A—acts on a pain pathway distinct from that targeted by opioid drugs.

The scientists used rodent models to show that a9a10 nicotinic acetylcholine receptors (nAChR) function as a pain pathway receptor and that RglA4 is an effective compound to block this receptor.

The pathway adds to a small number of non-opioid-based pathways that could be further developed to treat chronic pain.

The compound is able to work its way through the body in four hours, but the scientists found the beneficial effects lingered.

“We found that the compound was still working 72 hours after the injection, still preventing pain,” Michael McIntosh, professor of psychiatry at the University of Utah Health Sciences, said in a statement. “What is particularly exciting about these results is the aspect of prevention.

“Once chronic pain has developed, it is difficult to treat,” he added. “This compound offers a potential new pathway to prevent chronic pain from developing in the first place and also offers a new therapy to patients with established pain who have run out of options.”

In previous research, scientists showed that RgIA was effective in rodents, but the scientists wanted to ensure they had a compound that would work in humans.

To test this, the research team used synthetic chemistry to engineer 20 analogs of the compound and found that the analog RgIA4 was tightly bound to the human receptor.

They then tested whether the compound relieved plan by administering it to rodents that were exposed to a chemotherapy drug that causes extreme cold sensitivity, as well as hypersensitivity to touch.

“Interactions that are not normally painful, like sheets rubbing against the body or pants against the leg, becomes painful,” McIntosh said. “We feel that drugs that work by this pathway may reduce burden of opioid use.”

While the untreated rodents experienced pain after exposure to the drug, the rodents given the compound did not experience pain.

This demonstrated that a9a10 nAChR acts as a pain pathway receptor and that RgIA4 prevents the receptor from being activated.

“RgIA4 works by an entirely new pathway, which opens the door for new opportunities to treat pain,” McIntosh said.   

The research team plans on continuing pre-clinical testing to investigate the safety and effectiveness of the new drug therapy.

According to the Centers for Disease Control and Prevention, 91 Americans die every day from an opioid overdose.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE